Zivo Bioscience prices $4M share and warrant offering at $2.67 combined price

Zivo Bioscience announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 1,498,130 shares of common stock, or pre-funded warrants in lieu thereof, in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the company also agreed to issue and sell to the investor Series A warrants to purchase up to an aggregate of 1,498,130 shares of common stock and Series B warrants to purchase up to an aggregate of 1,498,130 shares of common stock. The combined effective offering price for each share of common stock, or pre-funded warrant in lieu thereof, and accompanying Series A and Series B warrant is $2.67. The gross proceeds to the company from the registered direct offering and concurrent private placement are estimated to be approximately $4M before deducting the placement agent’s fees and other estimated offering expenses payable by the company. Maxim Group is acting as the sole placement agent in connection with the offering.